Year archive

Active Biotech — 2012 filings

All 58 regulatory filings released by Active Biotech (ACTI) in 2012, sourced directly from the official regulator.

58 Filings

2012 Period

2012 filings (58)

Filing	Released	Lang
Laquinimod highlights från Tevas investerardag den 11 december Investor Presentation	2012-12-12	Swedish
Laquinimod highlights from Teva Investor Day December 11 Investor Presentation	2012-12-12	English
Teva håller investerarmöte den 11 december Report Publication Announcement	2012-12-11	Swedish
Teva Investor Meeting December 11 Regulatory Filings	2012-12-11	English
Active Biotechs och Ipsens kliniska fas III-studie med tasquinimod i prostatacancer fullrekryterad Regulatory Filings	2012-12-10	Swedish
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer Regulatory Filings	2012-12-10	English
Active Biotech's election committee appointed AGM Information	2012-11-15	English
Active Biotechs valberedning utsedd AGM Information	2012-11-15	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-11-09	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-11-09	English
Active Biotech AB Delårsrapport januari - september 2012 Interim / Quarterly Report 9M 2012	2012-11-09	Swedish
Active Biotech AB Interim report January - September 2012 Interim / Quarterly Report 9M 2012	2012-11-09	English
POSITIVA FAS IIa-DATA FÖR LAQUINIMOD FÖR BEHANDLING AV AKTIV CROHNS SJUKDOM Regulatory Filings	2012-10-22	Swedish
PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE Regulatory Filings	2012-10-22	English
Active Biotechs samarbetspartner Ipsen inleder en "proof of concept"-studie med tasquinimod i ytterligare cancerindikationer Regulatory Filings	2012-10-19	Swedish
Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications Regulatory Filings	2012-10-19	English
Ipsen inleder en underhållsterapi fas II-studie med tasquinimod i kastratresistent metastaserad prostatacancer Regulatory Filings	2012-10-03	Swedish
Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod Regulatory Filings	2012-10-03	English
Tasquinimod biomarkörsdata från fas II presenterade på ESMO 2012 Regulatory Filings	2012-10-01	Swedish
Tasquinimod Biomarker Phase II data presented at ESMO 2012 Regulatory Filings	2012-10-01	English
Active Biotech presenterar på Rodman & Renshaw Annual Global Investment Conference Investor Presentation	2012-09-06	Swedish
Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference Investor Presentation	2012-09-06	English
Interim / Quarterly Report 2012 Interim / Quarterly Report H1 2012	2012-08-10	English
Interim / Quarterly Report 2012 Interim / Quarterly Report H2 2012	2012-08-10	Swedish
TEVA PÅBÖRJAR EN TREDJE FAS III-STUDIE MED LAQUINIMOD I TABLETTFORM FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS Regulatory Filings	2012-08-08	Swedish
TEVA TO INITIATE THIRD PHASE III TRIAL OF ORAL LAQUINIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS Regulatory Filings	2012-08-08	English
ACTIVE BIOTECH MEDDELAR ATT DET EUROPEISKA LÄKEMEDELSVERKET ACCEPTERAT REGISTRERINGSANSÖKAN AV LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MS OCH UTVÄRDERINGSPROCESSEN PÅBÖRJAS Regulatory Filings	2012-07-17	Swedish
ACTIVE BIOTECH ANNOUNCE THAT EUROPEAN MEDICINES AGENCY ACCEPTS START OF SCIENTIFIC REVIEW OF THE MARKETING AUTHORIZATION APPLICATION FOR LAQUINIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS Regulatory Filings	2012-07-17	English
Active Biotechs and Ipsens läkemedelskandidat tasquinimod uppvisar förlängd överlevnadstid för kastratresistenta prostatacancerpatienter Earnings Release FY 2012	2012-06-04	Swedish
Active Biotech's and Ipsen's Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer Regulatory Filings	2012-06-04	English
Active Biotech presenterar på Jefferies 2012 Global Healthcare Conference Investor Presentation	2012-05-31	Swedish
Active Biotech to Present at the Jefferies 2012 Global Healthcare Conference Investor Presentation	2012-05-31	English
Active Biotech inbjuder till Kapitalmarknadsdag Investor Presentation	2012-05-29	Swedish
Active Biotech invites to Capital Markets Day Regulatory Filings	2012-05-29	English
600 patienter rekryterade i Active Biotechs och Ipsens kliniska fas III-studie med tasquinimod Regulatory Filings	2012-05-21	Swedish
600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study Earnings Release H2 2012	2012-05-21	English
Active Biotech och Ipsen presenterar överlevnadsdata från fas II-studien av tasquinimod på 2012 ASCO Annual Meeting Regulatory Filings	2012-05-18	Swedish
Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting Regulatory Filings	2012-05-18	English
Årsstämma i Active Biotech AB AGM Information	2012-05-11	Swedish
Annual General Meeting of Active Biotech AB AGM Information	2012-05-11	English
Annual Report 2012 Annual Report Q1 2012	2012-05-01	English
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-04-26	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-04-26	English
Annual Report 2011 Annual Report FY 2011	2012-04-17	Swedish
Årsredovisning 2011 Active Biotech AB (publ) Report Publication Announcement	2012-04-17	Swedish
Annual Report 2011 Active Biotech AB (publ) Report Publication Announcement	2012-04-17	English
Active Biotech: Kallelse till årsstämma AGM Information	2012-04-11	Swedish
Active Biotech: Notice of Annual General Meeting of Shareholders AGM Information	2012-04-11	English
Fas III-studien med Tevas orala laquinimod publicerad i The New England Journal of Medicine påvisar den kliniska nyttan för patienter med multipel skleros Regulatory Filings	2012-03-15	Swedish
Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients Earnings Release H2 2012	2012-03-15	English
Active Biotech och Ipsen presenterar på konferensen 27th European Association of Urology (EAU) för första gången långtidssäkerhetsdata från fas II-studien av tasquinimod (TASQ) Regulatory Filings	2012-02-24	Swedish
Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress Legal Proceedings Report	2012-02-24	English
Annual Report 2011 Annual Report FY 2011	2012-02-16	Swedish
Interim / Quarterly Report 2011 Interim / Quarterly Report FY 2011	2012-02-16	English
Active Biotechs prostatacancerprojekt TASQ i fas I klinisk studie som kombinationsterapi Regulatory Filings	2012-01-23	Swedish
Active Biotech's Prostate Cancer Project TASQ in Phase I Combination Therapy Trial Regulatory Filings	2012-01-23	English
Active Biotech presenterar på JP Morgan 30th Annual Healthcare Conference Regulatory Filings	2012-01-04	Swedish
Active Biotech to Present at the JP Morgan 30th Annual Healthcare Conference Regulatory Filings	2012-01-04	English

Filings by year

2026 11 filings
2025 41 filings
2024 45 filings
2023 32 filings
2022 42 filings
2021 48 filings
2020 41 filings
2019 45 filings
2018 38 filings
2017 33 filings
2016 40 filings
2015 40 filings
2014 49 filings
2013 58 filings
2012 58 filings
2011 56 filings
2010 62 filings
2009 55 filings
2008 28 filings
2007 8 filings